Skip to main content

24-09-2020 | Breast cancer | Video

ESMO 2020 | Atezolizumab–nab-paclitaxel improves PD-L1-positive metastatic TNBC survival

Leisha Emens takes us through the final overall survival analysis of the IMpassion130 study supporting the use of atezolizumab plus nab-paclitaxel in certain subsets of patients with metastatic triple-negative breast cancer, and outlines the key unmet needs (5:13).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.